Other Targets

Cat. No.

AT0226

CAS No.

1189541-98-7

Sarilumab

Synonyms: Anti-Human IL6Rα; Human Antibody

Sarilumab is a recombinant human monoclonal antibody of the immunoglobulin G1 subclass, specifically targeting the alpha subunit of the human interleukin-6 receptor (IL-6Rα). As an antagonist to IL-6, Sarilumab binds with high affinity to IL-6Rα, effectively inhibiting both cis and trans signaling pathways mediated by IL-6. This inhibition plays a crucial role in modulating inflammatory responses, making Sarilumab a valuable tool for investigating the pathophysiology and potential therapeutic interventions for rheumatoid arthritis.

Cat. No.

AT0261

Anti-IGFBP2 Antibody (M14)

The Anti-IGFBP2 Antibody (M14) is a human monoclonal antibody that exhibits high-affinity binding to insulin-like growth factor-binding protein 2 (IGFBP2). This antibody effectively inhibits the interaction between IGFBP2 and insulin-like growth factor 1 (IGF1), thereby blocking IGFBP2's biological activity. The Anti-IGFBP2 Antibody (M14) has been demonstrated to inhibit endothelial cell recruitment, a critical process in tumor angiogenesis and metastasis, thereby impeding the progression of human metastatic cancers. This product is pivotal for research focused on cancer biology, particularly in studies exploring mechanisms of tumor growth and metastasis.

Cat. No.

AT0300

Anti-CD163 Antibody (OR2805)

Anti-CD163 (OR2805) is a human monoclonal antibody of the IgG1 subclass designed to specifically target CD163, also known as scavenger receptor cysteine-rich type 1 protein M130. This antibody exhibits potential immunomodulating and antineoplastic properties by selectively binding to CD163, which is prominently expressed on immunosuppressive tumor-associated macrophages (TAMs) within the tumor microenvironment (TME). By binding to CD163, Anti-CD163 (OR2805) effectively inhibits the interaction of CD163 with its natural ligands, thereby modulating the immunosuppressive activity of TAMs and potentially enhancing antitumor immune responses. This mechanism positions Anti-CD163 (OR2805) as a valuable tool for research in cancer immunology and therapeutic development.

Cat. No.

AT0444

CAS No.

2642374-04-5

Patecibart

Synonyms: Getagozumab; GMA-301

Patecibart is a humanized IgG4-kappa monoclonal antibody designed to specifically target and inhibit the endothelin receptor type A (EDNRA). As an endothelin receptor antagonist, it plays a critical role in modulating vascular function by blocking the binding of endothelin-1 to its receptor, potentially alleviating conditions associated with vascular dysfunction and constriction. This antibody is pivotal for research focused on cardiovascular diseases, pulmonary arterial hypertension, and other endothelin-related pathologies.

Cat. No.

AT0499

CAS No.

1417158-65-6

Xentuzumab

Synonyms: BI 836845; Anti-Human IGF1 and IGF2 Recombinant Antibody

Xentuzumab (BI836845) is a recombinant human monoclonal antibody specifically designed to target and neutralize the insulin-like growth factors IGF1 and IGF2. By binding to these ligands, Xentuzumab effectively inhibits their role in promoting cellular growth and proliferation. Additionally, this antibody suppresses the activation of AKT, a critical kinase in the PI3K/AKT signaling pathway, further impeding oncogenic signaling. This dual mechanism of action makes Xentuzumab a valuable tool in research focused on cancer biology, particularly in studies exploring the regulation of growth factor-mediated signal transduction and its impact on cellular behaviors.

Cat. No.

AT0847

CAS No.

2485020-60-6

Elarekibep

Synonyms: PRS-060; AZD1402

Elarekibep (PRS-060/AZD1402) is a potent, long-acting full antagonist of the IL-4 receptor alpha (IL-4Ra), characterized by high affinity and slow dissociation rates. This agent is specifically designed for the study of Type 2 endotype asthma, providing a valuable tool for research into the pathophysiology and potential therapeutic interventions for this condition.

Cat. No.

AT0907

CAS No.

2226393-85-5

Avdoralimab

Synonyms: IPH 5401; Anti-C5aR1 mAb

Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody designed to selectively target and inhibit the complement C5a receptor 1 (C5aR1). By blocking the interaction between C5aR1 and its ligand C5a, Avdoralimab effectively prevents receptor activation, offering a therapeutic strategy for the study of complement-driven inflammatory diseases and solid tumors. This antibody is pivotal for researchers focusing on the role of the complement system in pathology and the therapeutic potential of complement inhibition.

Cat. No.

AT1314

CAS No.

1312797-14-0

Parsatuzumab

Synonyms: Anti-EGFL7; RG 7414

Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody designed to function as an immunomodulator by targeting and binding to the epidermal growth factor-like domain 7 (EGFL7). This antibody selectively inhibits the interaction between EGFL7 and endothelial cells, which may impede vascular regrowth and modulate the effects of vascular endothelial growth factor (VEGF) inhibition. Parsatuzumab is primarily researched for its potential applications in the regulation of angiogenesis and tumor microenvironment modulation.

Cat. No.

AT1396

ASK-8007

ASK 8007 is a monoclonal antibody designed to target and neutralize osteopontin. This antibody is specifically engineered for high specificity and affinity to osteopontin, making it an ideal tool for research focused on the role of osteopontin in various biological processes and diseases, such as inflammation, cancer progression, and tissue remodeling. ASK 8007 is suitable for a range of applications including Western blot, immunohistochemistry, and ELISA.

Cat. No.

AT1448

CAS No.

380610-22-0

Talizumab

Synonyms: TNX 901; Anti-Human IgE Fc Recombinant Antibody

Talizumab (TNX 901) is a humanized IgG1 monoclonal antibody designed to target and neutralize immunoglobulin E (IgE). This antibody is specifically engineered for the treatment and study of allergic reactions and other conditions mediated by excessive or inappropriate IgE responses.

Cat. No.

AT1557

CAS No.

2574438-65-4

Belrestotug

Synonyms: EOS-448; EOS884448; GSK4428859A

Belrestotug (EOS-448) is a human immunoglobulin G1 kappa (hIgG1 kappa) antibody that acts as an antagonist to TIGIT (VSIG9, VSTM3). This monoclonal antibody exhibits antineoplastic activity, targeting and modulating immune responses that are critical in the context of oncology research. Belrestotug is designed for the study of immune checkpoint pathways and their role in cancer immunotherapy.